Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2005

View Archived Issues

Novel peptide enhances the effects of BMP-2 in vitro

Antisoma to acquire Aptamera

Isis restructures

Lexicon advances two drug discovery programs into preclinical development

Millennium reviews 2004 milestones, looks forward to 2005

Phase III study planned for Mylinax in MS

RC-1291 receives fast track designation for cancer anorexia/cachexia

Taxotere approved for two new indications in Europe

Unique dual-binding AChE inhibitor with potent Abeta antiaggregating activity

European Rotarix filing sparks milestone payment to Avant

Biolex seeks approvals for phase I trials of BLX-883

Spectrum completes enrollment of phase II EOquin trial

Traficet-EN studied in phase II for IBD

GX15-070 enters phase I/II trial in CLL, receives orphan drug status

Aventis Pasteur changes name to sanofi pasteur

Samaritan drives progress of SP-01A for HIV

Raven Biotechnologies begins phase I/IIa trial of RAV-12 in GI cancers

TRU-015 enters phase I for rheumatoid arthritis

Phase II data on the efficacy of squalamine in wet AMD

A valopicitabine plus pegylated interferon regimen shows promise in hepatitis C

Juvantia develops a novel superagonist of human somatostatin receptor subtype 4

CB-03-01: a novel, selective androgen antagonist for topical use

Novel dual pharmacophore directly modulates cardiac function

Amgen's thrombopoietin receptor ligand AMG-531 tested in healthy individuals

New agents for Alzheimer's disease claimed by De Novo

Antibacterial ketolides described by Chiron scientists

Researchers at Actelion disclose orexin receptor antagonists

GSK team identifies new 5-HT5A receptor ligands for CNS disorders

HIV integrase inhibitors in early development at Bristol-Myers Squibb

Roche scientists prepare and test new agents for cancer

Antiinfective agents claimed by GlaxoSmithKline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...